Acer Therapeutics Inc (fka ACER)

[TheFinalCD]

This is the email I got back from ACER after pleading for a PR (lol)


looks like the info is not new, and already public info, so now I get why the debt holders sold it off from 7.67




-----Original Message-----
From: Investors <[e-mail]>
To: Investors <[e-mail]>; [e-mail] <[e-mail]>
Sent: Wed, May 20, 2020 9:05 am
Subject: RE: Formal Press Release **NEEDED***

Jeremiah:



Thank you for your interest in Acer Therapeutics. The data we referenced yesterday and this morning are from publications already posted on our website and cited in our current investor presentation, which is also posted on our website, and follows last week’s press releases. The emetine data included in the publications on our website and the subject of our tweets this week are based on published in vitro data.

Please see the following links to our:



Emetine Press Release 5/11/20

https://www.acertx.com/2020/05/11/acer-therapeutics-to-develop-emetine-as-potential-covid-19-treatment-in-collaboration-with-national-center-for-advancing-translational-sciences-one-of-the-national-institutes-of-health/



Q1 Earnings Release 5/14/20

https://www.acertx.com/2020/05/14/acer-therapeutics-reports-first-quarter-2020-financial-results-and-provides-corporate-update/

[Letsgosilver]

I bought at 5.75 thinking I was getting a dip but it proceeded to bleed out for the next 4 hours as I averaged down literally 20 times tapping out at 4.26. Now I have 4 grand in a ticker I knew nothing about a few hours ago with a 4.90 average. Do I have any hope any time soon?

[TheFinalCD]

ACER 3.95 needs to PR what they Tweeted today, could be right back to 7.74 hi hit today

https://www.nature.com/articles/s41586-020-2332-7_reference.pdf



Acer Therapeutics’ emetine significantly inhibits SARS-CoV-2 replication at non-toxic concentrations. Nature, May 2020. Bojkova D, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. https://tinyurl.com/yam5nxx4 #COVID-19 #SARS-CoV-2 #emetine

Acer Therapeutics’ emetine significantly inhibits SARS-CoV-2 replication at non-toxic concentrations. Nature, May 2020. Bojkova D, et al. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. https://t.co/nawiIJj0te #COVID-19 #SARS-CoV-2 #emetine

— Acer Therapeutics (@AcerTherapeutic) May 19, 2020

ACER Covid-19 Press Release May 11, 2020 https://finance.yahoo.com/news/acer-therapeutics-develop-emetine-potential-200510483.html

small float of only 7m and todays volume was over 2m

https://www.finviz.com/quote.ashx?t=ACER&ty=c&ta=1&p=d



CORPORATE WEB SITE https://www.acertx.com/
ACER PIPELINE https://www.acertx.com/rare-disease-research/


















AABB AAWC ABMC ACB ACB ALL ALPP AMRN AMZN ANY ATWT BRNW CAN CAPR CBDD CIVX CYDY DBMM DECN ERBB FUNN GMGI IMIMF IMO INO IPIX KNOS LOFB MARK MCTC MCTC MRNA NNDM NUGN NUGS OWCP PASO PBIO PCTL PRED PUMP RCPIQ RXMD SBES SEGN SPOM SRNE THC TLSS TPTW TRON TTOO VGTL VRUS




Board Rate* Posts Today News Quote** Last Change Chg% Volume ?***
1 Kronos Advanced Technologies (KNOS) 967% 890 KNOS 0.0345 0.0199 136.30% 96,554,460
2 South Beach Spirits Inc. (SBES) 719% 115 SBES 0.0067 0.00185 38.14% 33,006,005
3 AG Mortgage Investment Trust, Inc. (MITT) 686% 48 MITT 2.89 0.18 6.64% 6,254,753
4 HEAT BIOLOGICS INC (HTBX) 600% 48 HTBX 0.765 0.162 26.87% 29,609,592
5 Titan Medical Inc. (TMDI) 482% 53 TMDI 0.2998 0.0247 8.98% 8,835,642
6 PBS Holding Inc (PBHG) 433% 39 PBHG 0.0002 0.0 0.00% 9,521,112
7 Leap of Faith Beverages Inc. (LOFB) 400% 56 LOFB 0.35 0.04 12.90% 100,547
8 CTR Investments & Consulting Inc. (CIVX) 382% 229 CIVX 0.0017 0.0005 41.67% 104,097,378
9 RushNet Inc. (RSHN) 371% 89 RSHN 0.0003 0.0001 50.00% 16,245,033
10 Energy 1 Corporation (EGOC) 353% 53 EGOC 0.0003 0.0 0.00% 117,119,169
11 Inpixon (INPX) 343% 24 Recent News for INPX INPX 1.29 0.1 8.40% 22,406,568
12 CBD Denver Inc. (CBDD) 316% 101 CBDD 0.00107 0.00027 33.75% 99,869,985
13 Rennova Health Inc. (RNVA) 305% 131 RNVA 0.00015 0.0 0.00% 65,952,892
14 YaSheng Group (HERB) 300% 63 HERB 0.06 0.035 140.00% 118,779
15 Medical Marijuana, Inc. (MJNA) 300% 24 MJNA 0.0197 0.005 34.01% 47,841,929
16 $Rig's Platinum Penny Picks 296% 83
17 GME Innotainment Inc. (GMEV) 289% 26 GMEV 0.008 -0.0004 -4.76% 7,952,560
18 Potnetwork Holdings Inc. (POTN) 280% 28 POTN 0.0136 -0.000075 -0.55% 7,966,601
19 Digital Brand Media and Marketing Group, Inc. (DBMM) 277% 97 DBMM 0.0019 0.0 0.00% 117,100
20 Greater Cannabis Company Inc. (GCAN) 275% 77 GCAN 0.0065 0.0013 25.00% 956,232
21 Asia Broadband, Inc. (AABB) 273% 101 AABB 0.0037 0.0013 54.17% 22,792,109
22 Brewbilt Mfg. Inc. (BBRW) 262% 34 BBRW 0.007 0.0002 2.94% 13,117,369
23 Weyland Tech Inc. (WEYL) 253% 38 WEYL 2.14 -0.01 -0.47% 6,590
24 Innovation Pharmaceuticals Inc. (IPIX) 250% 287 IPIX 0.1581 0.016 11.26% 6,434,956
25 OWC Pharmaceutical Research Corp. (OWCP) 249% 102 OWCP 0.0098 0.0013 15.29% 17,598,389
26 Helios and Matheson Information Technology Inc. (HMNY) 245% 27 HMNY 0.0013 0.00055 73.33% 112,512,765
27 Moderna Inc. (MRNA) 240% 96 Recent News for MRNA MRNA 71.67 -8.33 -10.41% 64,956,084
28 Apple Rush Company, Inc (APRU) 239% 55 APRU 0.0024 -0.0002 -7.69% 8,248,396
29 Pacific Ventures Group Inc. (PACV) 238% 81 Recent News for PACV PACV 1.63 -0.26 -13.76% 47,434
30 Indoor Harvest Corp (INQD) 237% 83 Recent News for INQD INQD 0.0003 -0.0001 -25.00% 68,211,393
31 Simlatus Corp. (SIML) 232% 58 SIML 0.006 -0.0073 -54.89% 21,764,073
32 Marker Therapeutics Inc (MRKR) 229% 16 MRKR 2.57 0.225 9.59% 1,831,453
33 Patient Access Solutions Inc. (PASHealth) (PASO) 227% 150 PASO 0.0239 -0.00085 -3.43% 7,548,048
34 Renewable Energy & Power (RBNW) 226% 122 RBNW 0.003265 0.000365 12.59% 105,694,406
35 Mymetics Corporation (MYMX) 223% 69 MYMX 0.04 0.00445 12.52% 320,878
36 Cruzani Inc. (CZNI) 220% 33 CZNI 0.0012 -0.0002 -14.29% 9,313,614
37 Voip-Pal.Com Inc. (VPLM) 217% 52 VPLM 0.0108 -0.0002 -1.82% 451,506
38 NanoLogix, Inc. (NNLX) 213% 34 NNLX 0.15 -0.017 -10.18% 1,088,231
39 Next Green Wave (NXGWF) 206% 35 NXGWF 0.091 -0.0003 -0.33% 400,100
40 Transportation and Logistics Systems Inc. (TLSS) 202% 922 TLSS 0.0412 0.0098 31.21% 76,133,571
41 Ritter Pharmaceuticals Inc (RTTR) 200% 24 Recent News for RTTR RTTR 0.519 -0.121 -18.91% 21,529,443
42 iQSTEL Inc. (IQST) 200% 68 Recent News for IQST IQST 0.0607 0.0032 5.57% 1,639,546
43 SMART MONEY GROUP 198% 371
44 GRN Holding Corp. (GRNF) 196% 112 GRNF 0.259 0.022595 9.56% 322,998
45 Quantum Materials Corporation (QTMM) 196% 47 QTMM 0.02295 -0.00155 -6.33% 2,130,035
46 Fannie Mae (FNMA) 195% 242 FNMA 1.84 0.16 9.52% 9,406,010
47 Seanergy Maritime Holdings Corp. (SHIP) 191% 21 SHIP 0.145 -0.003 -2.03% 46,955,023
48 NorthWest Biotherapeutics Inc. (NWBO) 188% 229 NWBO 0.22 0.014 6.80% 2,873,387
49 American Airlines (AAL) 186% 13 AAL 9.64 -0.23 -2.33% 62,245,442
50 BitFrontier Capital Holdings Inc. (BFCH) 182% 20 BFCH 0.0076 -0.0003 -3.80% 1,069,493
*Rate is the change in posting activity in the past 24 hours vs. the average from the prior 7 days
** Market data is delayed 15-20 minutes and is updated once per minute.

[swingingRichard]

*** ACER Stock Analyzer Chart 4/23 ***

Let's see what happens . . .

[ADVFN_bioking]

MEGA rebound play here , if clinical results are positive stock will explode because of its extremely low float

[ADVFN_bioking]

big news coming this Q

[ADVFN_bioking]

low float stock

[ADVFN_bioking]

i like it

[ClayTrader]

* * $ACER Video Chart 06-29-2019 * *

Link to Video - click here to watch the technical chart video

[ALERTS100%to10000%GAIN]

ACER coming week going to $10.00

[ALERTS100%to10000%GAIN]

bought 5k here ACER

[ErnieBilco]

OMG they cut the floor out from under this....

I'mmmmmmm fallllllllllinggggggggg

And I can't get up

[ErnieBilco]

My read says that $3.61 could be pretty close to the bottom unless we get a really red market to drop it further.

[WHITTENHALLJR]

Got an eye on it... I've learned to be patient... I want to grab it at the very bottom

[ErnieBilco]

Glad I didn't load up yesterday. That allowed me to avg down today, will add if I get another 10% drop.

[ALERTS100%to10000%GAIN]

ACER from $19.36 to $4.12 in a day crazyyy here

[ALERTS100%to10000%GAIN]

ACER~~4.12 down 78%% RED today

[ALERTS100%to10000%GAIN]

ACER~~FDA Rejects Acer Therapeutics' Rare Disease Drug, Calls for New Trial
Published: Jun 25, 2019 By Mark Terry

Reject

Newton, Mass.-based Acer Therapeutics received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Edsivo (celiprolol). Edsivo was being developed for vascular Ehlers-Danlos syndrome (vEDS).

EDS is a group of hereditary diseases of the connective tissue. vEDS is the most severe subtype. Patients with vEDS suffer from life-threatening arterial dissections and ruptures, in addition to intestinal and uterine ruptures. The average mortality is 51 years of age. A study commissioned by the company identified 4,169 vEDS patients in the U.S. from a database of about 190 million unique patients.

The CRL indicated the company will need to run an “adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS.”

The company plans to request a meeting with the FDA to discuss the rejection.

Click to take the 2019 ideal employer survey.

Acer’s NDA was based on results from the analysis of a 2010 European clinical trial that involved 53 patients. However, the agency was concerned about the small trial size.

The company stock took a hit at the news, dropping 81%.

The CRL was undoubtedly a blow. On May 14, at the company’s first-quarter financial report, Chris Schelling, chief executive officer and company founder indicated “we have made significant progress in preparing for a potential launch of Edsivo, including the addition of seasoned commercial and medical affairs leaders with extensive sales, marketing, market access and product launch experience in orphan and ultra-orphan markets.”

In April the company published long-term data from a cohort of COL3A1-positive vEDS patients in the Journal of the American College of Cardiology (JACC). That included up to 17 years of safety data in the population with survival curve analysis showing that patients who did not receive celiprolol had much worse outcomes than those receiving the drug. They also cited a relative decrease in hospitalization rates for acute arterial events during that period when a majority of patients were on celiprolol.

Schelling says they expect to respond to the FDA in the third quarter of this year.



The company was founded in 2013. Its lead candidate is ACER-001, being developed for patients with Maple Syrup Urine Disease (MSUD). It is an immediate release formulation of sodium phenylbutyrate. It is also being evaluated for urea cycle disorders. MSUD is an autosomal recessive metabolic disorder, which results in a distinctive sweet odor of infants’ urine. If untreated, symptoms can be neurological dysfunction, including lethargy, irritability and poor feeding, followed by abnormal movements, spasticity, convulsions and coma. Progressive brain damage and death can occur without treatment.

Earlier this year the company licensed osanetant from Sanofi, for which it hopes to begin trials for neuroendocrine-related disorders. Sanofi unsuccessfully attempted to develop it for schizophrenia. Osanetant is a selective, non-peptide tachykinin NK3 receptor antagonist.

At the time, Schelling stated, “The drug perfectly fits Acer’s acquisition and development model of de-risked assets—it already has robust non-clinical, pharmacokinetic and human safety data, and based on recent studies involving antagonism of the NK3 receptor, we believe it can be successfully repurposed to treat a variety of neuroendocrine disorders.”

Two years ago, Acer went public via a reverse merger with Texas-based Opexa Therapeutics, receiving $15.7 million financing from TVM Capital at the same time.

Email this

Facebook

Twitter

LinkedIn

Pinterest

Reddit